z-logo
open-access-imgOpen Access
Infigratinib (Truseltiq®)
Author(s) -
Michelle Sproat
Publication year - 2022
Publication title -
oncology times
Language(s) - Uncategorized
Resource type - Journals
eISSN - 1548-4688
pISSN - 0276-2234
DOI - 10.1097/01.cot.0000839944.24360.6f
Subject(s) - medicine , fibroblast growth factor receptor , regimen , cohort , oncology , progressive disease , tyrosine kinase inhibitor , receptor tyrosine kinase , cancer , gastroenterology , fibroblast growth factor , chemotherapy , receptor

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here
Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom